Your browser doesn't support javascript.
Retrospective Analysis of Clinical Laboratory Parameters, Therapeutics and Outcome in Patients Infected with SARS-CoV2.
Sengupta, Sohini; Handoo, Anil; Pande, Rajesh; Kapoor, R K.
  • Sengupta S; Department of Clinical Biochemistry, BLK-MAX Super Speciality Hospital, Delhi, India.
  • Handoo A; Department of Laboratory Services, BLK-MAX Super Speciality Hospital, Delhi, India.
  • Pande R; Department of Laboratory Services, BLK-MAX Super Speciality Hospital, Delhi, India.
  • Kapoor RK; Department of Critical Care Medicine, BLK-MAX Super Speciality Hospital, Delhi, India.
Indian J Clin Biochem ; 37(4): 480-486, 2022 Oct.
Article in English | MEDLINE | ID: covidwho-2075674
ABSTRACT
SARS-CoV-2 is the third coronavirus to have caused severe disease in humans in the last two decades, with approximately 5% of all patients and 20% of hospitalized patients experiencing severe symptoms, necessitating intensive care. The occurrence of Cytokine Storm has been implicated in the immune-pathogenesis of severe COVID-19. This is associated with cardiac injury, precipitated by cytokine mediated imbalance of coagulation and fibrinolysis, in the lung alveoli. In the absence of proven therapeutic agents, combinations of anti-viral drugs, immune-modulators and other adjunctive therapies have been tried in different clinical settings. A total of 128 confirmed cases of severe COVID-19 admitted to BLK-MAX Super Speciality Hospital between 16th of June to 31st of July, 2020 were included in this study. The correlation of age, gender, first value (on admission) of serum IL-6 and D-dimer, and impact of Tocilizumab and Remdesivir therapy on clinical outcome (28-day mortality), was evaluated in confirmed cases of severe COVID-19. The mortality rate was highest in the age group above 70 years. The incidence of death was significantly higher in males above 50 years, when age and gender were considered together. IL-6 and D-dimer levels >70 pg/mL and > 0.5µg FEU/mL respectively, were associated with poor outcome. 85.3% of patients treated with Remdesivir showed clinical improvement. When Tocilizumab and Remdisivir were administered together, 44.0% of patients survived while 56% expired. 79.7% of patients survived while 20.3% expired when neither Tocilizumab nor Remdesivir was administered.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study Language: English Journal: Indian J Clin Biochem Year: 2022 Document Type: Article Affiliation country: S12291-021-01009-5

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study Language: English Journal: Indian J Clin Biochem Year: 2022 Document Type: Article Affiliation country: S12291-021-01009-5